Cell and Gene Therapy Insights
Harnessing multiple immune pathways to drive anti-tumor activity
By Frank Borriello.
Abstract
“As a physician, my goal is to develop a therapy that all intended patients, and healthcare systems, can afford and deliver.”Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights , speaks with Dr Frank Borriello, CEO, Alloplex Biotherapeutics, about a non-engineered, autologous approach to cancer immunotherapy. They discuss the ENLYST platform and multi-pathway immune cell activation, the SUPLEXA manufacturing process, comparability across variable autologous starting material, durability, and persistence, and the potential of decentralized manufacturing to improve patient access. They also explore how in vivo and ex vivo CAR-T fit into the evolving cell therapy landscape.
Keywords
- CAR-T cell therapy research
- Immune system
- Comparability
- Ex vivo
- Cell therapy
- Genetic enhancement
- Immunotherapy
- Cell
- In vivo
- Open access
Source
Published in Cell and Gene Therapy Insights. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.